Thiodigalactoside shows antitumour activity by beta-galactoside-binding protein and regulatory T cells inhibition in oral squamous cell carcinoma

• Published in: Oral diseases 2016-07, Vol.22 (5), p.445-453
• Main Authors: Aggarwal, S, Das, SN
• Format: Article
• Language: English
• Subjects: angiogenesis; Angiogenesis Inducing Agents - pharmacology; Apoptosis - drug effects; beta-galactoside-binding protein; Carcinoma, Squamous Cell - blood supply; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - immunology; Carcinoma, Squamous Cell - pathology; CD4-Positive T-Lymphocytes - drug effects; CD4-Positive T-Lymphocytes - immunology; cell cycle; Cell Cycle - drug effects; Cell Line, Tumor; Cell Proliferation - drug effects; Dentistry; Galectins - pharmacology; Head and Neck Neoplasms - blood supply; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - immunology; Head and Neck Neoplasms - pathology; Humans; Interleukin-10 - immunology; Interleukins - immunology; Mouth Neoplasms - blood supply; Mouth Neoplasms - drug therapy; Mouth Neoplasms - immunology; Mouth Neoplasms - pathology; Oral cancer; Proteins; regulatory T cells; Squamous Cell Carcinoma of Head and Neck; T cell receptors; T-Lymphocytes, Regulatory - drug effects; T-Lymphocytes, Regulatory - immunology; T-Lymphocytes, Regulatory - pathology; thiodigalactoside; Thiogalactosides - pharmacology
• ISSN: 1354-523X; 1601-0825
• DOI: 10.1111/odi.12479

Objective Thiodigalactoside (TDG), a synthetic inhibitor of β‐galactoside‐binding protein (β‐GBP) suppresses tumour growth by inhibiting multiple cancer enhancing activities of β‐GBP. Hence, we attempted to understand whether disruption of β‐GBP functions and indirect inhibition of Treg cells by TDG affect the growth and establishment of oral cancer cells. Method The growth, morphology, cell cycle regulation, apoptosis induction and angiogenesis of oral cancer cell lines (SCC‐4, SCC‐9, SCC‐25) via MACS‐purified Treg cells were performed by MTT, propidium iodide (PI) staining, annexin‐V‐binding assay and ELISA respectively. Results Treatment with β‐GBP showed growth‐promoting effects on Tregs and oral cancer cells. However, the treatment with its inhibitor TDG resulted in inhibition of Treg subsets and also decreased the frequency of IL10+ and IL35+ Tregs indicating its immunomodulatory effects. Additionally, TDG treatment significantly (P